FMP
Salarius Pharmaceuticals, Inc.
SLRX
NASDAQ
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
2.69 USD
0.07 (2.6%)
InvestorPlace
Jul 23, 2024
Genomic therapeutic specialist Salarius Pharmaceuticals (NASDAQ: SLRX ) screamed higher Tuesday, with shares gaining 160% before paring back some of the gains to around 90%. Although no catalyst is apparent, the biotechnology firm revealed details about its at-the-market (ATM) offering recently.
Market Watch
May 9, 2023
Salarius Pharmaceuticals Inc.'s stock SLRX soared 33% in premarket trade Tuesday after the company said the U.S. Food and Drug Administration has lifted a partial clinical hold on a trial of a treatment for Ewing sarcoma, a rare and deadly form of cancer that occurs in bones or the soft tissue around bones. The treatment called seclidemstat, was being reviewed in a Phase 1/2 trial and had previously been granted Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designati...
GlobeNewsWire
Apr 4, 2023
HOUSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that management will present at the Diamond Equity Research Emerging Growth Invitational virtual investor conference taking place Wednesday, April 5th.
GlobeNewsWire
Jan 19, 2023
Dr. Aundrietta Duncan to discuss mechanism of action and SP-3164 activity in cancer models
GlobeNewsWire
Oct 19, 2022
HOUSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that Daniela Santiesteban, Ph.D., Salarius' director of targeted protein degradation development, will be presenting at the 5th Annual Targeted Protein Degradation Conference being held October 25-28 in Boston. Dr. Santiesteban...
GlobeNewsWire
Sep 20, 2022
HOUSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients fighting cancer and in need of new treatment options, today announced that management will present at the 2022 Ladenburg Thalmann Healthcare Conference being held on September 29th in New York City at the Sofitel Hotel. David Arthur, chief executive officer, will deliver a corporate presentation and participate in a “fireside chat...
Seeking Alpha
Aug 8, 2022
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX ) Q2 2022 Earnings Conference Call August 8, 2022 11:00 AM ET Company Participants Kim Golodetz - Senior Vice President, Principal, LHA Investor Relations David Arthur - Director and CEO Mark Rosenblum - Chief Financial Officer Dr. Daniela Santiesteban - Director, Protein Degradation, Development Conference Call Participants Ahu Demir - Ladenburg Operator Welcome to the Salarius Pharmaceuticals Second Quarter 2022 Financial Results and Business Update ...
Proactive Investors
Aug 2, 2022
VolitionRx (NYSE-A:VNRX) Limited has inked a pair of research and development collaborations that will develop targeted, adoptive cell therapies to treat cancer and help advance a drug designed to treat solid and hematologic cancers. First off, the company will collaborate with Xenetic Biosciences (NASDAQ:XBIO) Inc to evaluate the potential combination of Volition's Nu.Q NETs Test and Xenetic's DNase-Armored CAR T platform to develop proprietary adoptive cell therapies potentially targeting mult...
GlobeNewsWire
Jul 29, 2022
Conference Call and Live Audio Webcast Scheduled for 11:00 a.m. ET Conference Call and Live Audio Webcast Scheduled for 11:00 a.m. ET
GlobeNewsWire
May 18, 2022
HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other solid and hematological cancers, today announced that David Arthur, CEO of Salarius Pharmaceuticals, will be virtually presenting at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022.